StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

Design Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Design Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $58.78M, up 6.6% year over year. For fiscal 2025 it was $59.13M, up 33.3% from the year before. The highest annual figure on record is $59.13M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$59.13M+33.3%
FY2024Dec 31, 2024$44.35M-22.3%
FY2023Dec 31, 2023$57.06M+17.4%
FY2022Dec 31, 2022$48.61M+96.2%
FY2021Dec 31, 2021$24.78M+308.9%
FY2020Dec 31, 2020$6.06M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.39M+4.1%
Q1 FY2026Mar 31, 2026$14.38M-6.5%
Q4 FY2025Dec 31, 2025$13.43M+10.4%
Q3 FY2025Sep 30, 2025$14.59M+22.8%
Q2 FY2025Jun 30, 2025$15.74M+49.7%
Q1 FY2025Mar 31, 2025$15.38M+56.9%
Q4 FY2024Dec 31, 2024$12.16M+10.4%
Q3 FY2024Sep 30, 2024$11.88M-10.4%
Q2 FY2024Jun 30, 2024$10.52M-38.4%
Q1 FY2024Mar 31, 2024$9.80M-37.7%
Q4 FY2023Dec 31, 2023$11.01M-22.7%
Q3 FY2023Sep 30, 2023$13.26M-7.3%
Q2 FY2023Jun 30, 2023$17.06M+51.1%
Q1 FY2023Mar 31, 2023$15.73M+79.6%
Q4 FY2022Dec 31, 2022$14.26M+94.3%
Q3 FY2022Sep 30, 2022$14.30M+67.5%
Q2 FY2022Jun 30, 2022$11.30M+124.7%
Q1 FY2022Mar 31, 2022$8.76M+126.0%
Q4 FY2021Dec 31, 2021$7.34M+170.9%
Q3 FY2021Sep 30, 2021$8.54M+346.1%
Q2 FY2021Jun 30, 2021$5.03M+373.8%
Q1 FY2021Mar 31, 2021$3.88M+927.9%
Q4 FY2020Dec 31, 2020$2.71M–
Q3 FY2020Sep 30, 2020$1.91M–
Q2 FY2020Jun 30, 2020$1.06M–
Q1 FY2020Mar 31, 2020$377.00K–

More Design Therapeutics figures

See a number that looks wrong?